Fisher & Paykel Healthcare Corporation Limited announced today that it is reactivating its dividend reinvestment plan (DRP) for eligible shareholders residing in New Zealand, Australia and the United Kingdom.
Under the reactivated DRP, eligible shareholders may elect to reinvest all or part of their cash dividends in additional shares. A 3% discount will be applied when determining the price per share of shares issued under the DRP and will be applied in respect of the 2023 interim dividend and future dividends, until such time as the directors determine otherwise.
Shareholders that previously opted into the plan will remain enrolled unless they terminate their participation online at https://investorcentre.linkgroup.nz/ or by completing a cancellation form available upon request from the company’s registrar, Link Market Services.
Shareholders not previously enrolled who wish to participate in respect of the FY2023 interim dividend will need to opt into the plan via Link Market Services’ website at https://investorcentre.linkgroup.nz/ or return a physical participation form before 5pm on 12 December 2022. The plan offer document and participation form are available on the company’s website at www.fphcare.com/drp.
The strike price is calculated as the volume-weighted average sale price for an ordinary share, calculated on all price-setting trades of shares which took place through the NZX Main Board over a period of five trading days immediately following the dividend record date of 9 December 2022. The company will issue an announcement of the strike price, inclusive of the 3% discount, once calculated.
Fisher & Paykel Healthcare first introduced a dividend reinvestment plan in 2009 before suspending it in 2019.
For more information, please contact Link Market Services at operations@linkmarketservices.co.nz or +64 9 375 5998.
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in more than 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.
Ends
Media & Investor Contacts
|
Authorised by Fisher & Paykel Healthcare Corporation Limited’s Board of Directors.